乳腺癌分子亚型在新辅助化疗中的作用  

Molecular Subtypes of Breast Cancer in the Role of Neoadjuvant Chemotherapy

作　　者：刘佳杰[1] 张瑞明[2] 白俊文[2] 金山[2] 

机构地区：[1]内蒙古医学院 [2]内蒙古医学院附属医院普外科B区,内蒙古呼和浩特010050

出　　处：《内蒙古医学杂志》2012年第3期322-325,共4页Inner Mongolia Medical Journal

摘　　要：乳腺癌是妇女最常见的恶性肿瘤之一,其发病率占女性恶性肿瘤之首位。新辅助化疗已经成为治疗局部晚期乳腺癌的重要手段,不同化疗方案临床疗效有差异。为了让乳腺癌患者在新辅助化疗中获得最大获益,基于形态学的传统病理学分类以不能完全胜任患者的个体化治疗的要求。近年通过分子生物学标记的分子亚型分类在新辅助化疗中有着不同的生物学特征,本文就近年来有关乳腺癌分子亚型在新辅助化疗中的作用方面的研究作一综述。Breast cancer is one of the most common female malignant tumors,whose incidence rate of the first accounted for the female malignant tumor.Neoadjuvant chemotherapy has become a major therapeutic strategy for the treatment of locally advanced breast cancer.In order for patients with breast cancer during neoadjuvant chemotherapy to obtain the maximum benefit,based on the morphology of the traditional pathology classification to not fully competent patients in individual treatment requirements.In recent years by molecular markers molecular subtype classification in neoadjuvant chemotherapy with different biological features,this article analyzes the relevant molecular subtypes of breast cancer to neoadjuvant chemotherapy and the role of context.

关 键 词：乳腺癌 新辅助化疗 分子分型 

分 类 号：R737.9[医药卫生—肿瘤]